A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Was this article valuable?
Here are more articles you may enjoy.
Two Architects of Key State AI Laws Come to Washington to Do It Again
El NiƱo, Climate Change Supercharged Indonesia Fires, Study Says
Nvidia-Backed Fireworks AI Notifies Customers of Its Second Hack in Weeks
Navigating the Storm: A Claims Manager’s Guide to Class Action Exposure, Coverage and Reserves